Information Provided By:
Fly News Breaks for August 6, 2015
SGMO
Aug 6, 2015 | 11:42 EDT
Wedbush recommends buying Sangamo on weakness for 2016. The firm expects significant clinical progress in the next 6-18 months and reiterates its Outperform rating and $30 price target.
News For SGMO From the Last 2 Days
There are no results for your query SGMO